Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

Caroline Holm Norgaard, Sarah Friedrich, Charlotte Thim Hansen, Thomas Gerds, Clive Ballard, Daniel Vega Moller, Lotte Bjerre Knudsen, Kajsa Kvist, Bernard Zinman, Ellen Holm, Christian Torp-Pedersen*, Lina Steinrud Morch

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

92 Citationer (Scopus)
17 Downloads (Pure)

Abstract

Introduction
People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.

Methods
We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).

Results
Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25–0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86–0.93 with yearly increased exposure to GLP-1 RAs).

Discussion
Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes
OriginalsprogEngelsk
Artikelnummer12268
TidsskriftAlzheimers & dementia-Translational research & clinical interventions
Vol/bind8
Udgave nummer1
Antal sider9
DOI
StatusUdgivet - 2022

Citationsformater